EarlyDiagnostics

📍 Los Angeles, United States🗓 Founded 2017👥 6 employees💰 Last funded 2017
Biotechnology Research🌐 earlydx.com
Website LinkedIn
EarlyDx is committed to providing cutting-edge non-invasive genomics technologies and best-in-class early disease diagnostics. Our proprietary cfDNA-based technologies, in combination with powerful AI algorithms, have shown great potential to transform non-invasive biomarker discovery, diagnostics, and precision medicine for almost any diseases, including cancers, aging, metabolic diseases, autoimmune diseases, imprinting diseases, and neurological diseases. Our key cfDNA-based best-in-class technologies include: 1. cfMethyl-seq: a powerful and cost-effective NGS solution to profile the cfDNA methylome 2. cfSNV: a cutting-edge computational tool to accurately call mutations directly from blood 3. cfTrack: for non-invasive monitoring of cancer MRD, recurrence, and evolution 4. EarlyDx-Cloud: a comprehensive bioinformatics data analysis platform for liquid biopsy Please check out our relevant publications in details: https://earlydx.com/technologies/publications/
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2017
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in EarlyDiagnostics?
EarlyDiagnostics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did EarlyDiagnostics last raise funding?
The most recent investment in EarlyDiagnostics recorded on gritt.io was in 2017.
When was EarlyDiagnostics founded?
EarlyDiagnostics was founded in 2017.
What industry is EarlyDiagnostics in?
EarlyDiagnostics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is EarlyDiagnostics based?
EarlyDiagnostics is headquartered in Los Angeles, United States.